<DOC>
	<DOCNO>NCT00002197</DOCNO>
	<brief_summary>The purpose study see safe give 1592U89 child ( age 6 month 14th birthday ) advance HIV infection treatment option available . The study also examine effect 1592U89 level HIV blood .</brief_summary>
	<brief_title>A Study 1592U89 HIV-Infected Children</brief_title>
	<detailed_description>This open-label , non-randomized study . All patient treat 1592U89 . Additionally , since optimal therapy usually include combine use 2 antiretroviral agent advanced patient , novel antiretroviral therapy may access commercial mean via compassionate use program . NOTE : 1592U89 administer single new agent add fail treatment regimen .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Intravenous immunoglobulin G. Erythropoietin , granulocyte colony stimulate factor granulocyte macrophage colony stimulate factor , management hematologic toxicity . Patients must : Documented HIV infection . High risk disease progression mortality define either follow : Viral load &gt; 100,000 copies/ml CD4 cell &lt; 15 % total lymphocyte count despite least 4 week therapy commercially available antiretrovirals result therapy due treatmentlimiting toxicity ZDV , 3TC , ddI ; HIVassociated encephalopathy refractory ZDVcontaining regimen . No access 1592U89 pediatric study patient could qualify inclusion . Parent legal guardian ability understand provide write consent patient participate trial . Study patient 13 year also give write informed consent whenever possible . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : In investigator 's opinion , patient unlikely comply requirement study . Renal failure require dialysis . Hepatic failure evident Grade 3 4 hyperbilirubinemia AST &gt; 10 X upper limit normal . Lifethreatening infection chronic disease may interfere take 1592U89 compromise patient 's safety . Patients follow prior condition exclude : Documented hypersensitivity 1592U89 nucleoside analogue . See Inclusion General Criteria .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>abacavir</keyword>
</DOC>